Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

220
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
220
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
Autoimmune Disorders01:29

Autoimmune Disorders

723
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
723
Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis.

Expert review of gastroenterology & hepatology·2024
Same author

Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis.

Digestive diseases and sciences·2023
Same author

Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis.

Digestive diseases and sciences·2023
Same author

Missing Causality and Heritability of Autoimmune Hepatitis.

Digestive diseases and sciences·2022
Same author

Examining micro-ribonucleic acids as diagnostic and therapeutic prospects in autoimmune hepatitis.

Expert review of clinical immunology·2022
Same author

Review article: targeting the B cell activation system in autoimmune hepatitis.

Alimentary pharmacology & therapeutics·2021

Related Experiment Video

Updated: Oct 4, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K

Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.

Albert J Czaja1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 200 First Street S.W., Rochester, MN, 55905, USA. czaja.albert@mayo.edu.

Digestive Diseases and Sciences
|February 11, 2022
PubMed
Summary

Biologic therapies show promise for refractory autoimmune hepatitis, targeting key pathways. Further research and comparative trials are needed to optimize efficacy and safety for this autoimmune liver disease.

Keywords:
Autoimmune hepatitisBiologic agentsRefractoryTherapy

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K

Related Experiment Videos

Last Updated: Oct 4, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K

Area of Science:

  • Immunology
  • Hepatology
  • Pharmacology

Background:

  • Autoimmune hepatitis (AIH) is a chronic liver disease with limited treatment options for refractory cases.
  • Biologic agents offer a potential new avenue for managing difficult-to-treat autoimmune hepatitis.
  • Current treatments for refractory AIH often fall short, creating an unmet clinical need.

Purpose of the Study:

  • To review existing biologic therapies for refractory autoimmune hepatitis.
  • To identify areas for improvement and expansion in biologic treatment strategies.
  • To advocate for comparative clinical trials in this therapeutic area.

Main Methods:

  • Systematic literature search of English abstracts in PubMed.
  • Selection and review of full-length articles.
  • Development of secondary and tertiary bibliographies for comprehensive data collection.

Main Results:

  • Several biologic agents, including Rituximab, Infliximab, low-dose recombinant Interleukin 2, and Belimumab, have shown laboratory improvements in small patient cohorts.
  • Ianalumab is currently undergoing clinical trials for AIH.
  • These targeted therapies, while effective, carry potential risks and side effects, necessitating careful monitoring.

Conclusions:

  • Biologic agents target crucial pathogenic pathways in autoimmune hepatitis.
  • Early results in refractory AIH are encouraging, supporting further investigation.
  • Future directions include identifying optimal targets, conducting rigorous clinical trials, and performing comparative evaluations to refine treatment protocols.